Sanofi Pre-Tax Profit Margin 2012-2025 | SNY
Current and historical pre-tax profit margin for Sanofi (SNY) from 2012 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Sanofi pre-tax profit margin for the three months ending September 30, 2025 was .
| Sanofi Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-09-30 | $46.78B | $8.43B | 18.01% |
| 2025-06-30 | $46.96B | $8.18B | 17.41% |
| 2025-03-31 | $47.02B | $8.06B | 17.14% |
| 2024-12-31 | $47.92B | $7.25B | 15.12% |
| 2024-09-30 | $53.03B | $6.67B | 12.58% |
| 2024-06-30 | $51.29B | $6.12B | 11.94% |
| 2024-03-31 | $50.68B | $6.57B | 12.96% |
| 2023-12-31 | $50.27B | $7.74B | 15.40% |
| 2023-09-30 | $49.01B | $12.13B | 24.75% |
| 2023-06-30 | $48.42B | $11.52B | 23.78% |
| 2023-03-31 | $48.20B | $11.01B | 22.85% |
| 2022-12-31 | $47.82B | $10.98B | 22.96% |
| 2022-09-30 | $48.72B | $10.22B | 20.98% |
| 2022-03-31 | $34.76B | $8.47B | 24.36% |
| 2021-09-30 | $35.03B | $8.73B | 24.91% |
| 2021-03-31 | $43.57B | $9.70B | 22.25% |
| 2020-09-30 | $42.75B | $8.86B | 20.71% |
| 2020-03-31 | $41.19B | $7.47B | 18.14% |
| 2019-09-30 | $41.49B | $6.12B | 14.76% |
| 2019-03-31 | $41.50B | $6.08B | 14.64% |
| 2018-03-31 | $41.43B | $5.98B | 14.44% |
| 2017-12-31 | $40.92B | $6.25B | 15.28% |
| 2017-09-30 | $40.25B | $6.63B | 16.48% |
| 2017-06-30 | $39.59B | $6.79B | 17.16% |
| 2017-03-31 | $39.14B | $6.89B | 17.59% |
| 2016-12-31 | $38.41B | $6.28B | 16.36% |
| 2016-09-30 | $39.27B | $7.14B | 18.17% |
| 2016-06-30 | $39.37B | $6.82B | 17.33% |
| 2016-03-31 | $41.16B | $6.87B | 16.68% |
| 2015-09-30 | $42.97B | $6.43B | 14.95% |
| 2015-06-30 | $43.92B | $6.27B | 14.27% |
| 2014-06-30 | $44.70B | $6.92B | 15.49% |
| 2013-06-30 | $45.22B | $6.43B | 14.23% |
| 2012-06-30 | $46.75B | $8.86B | 18.96% |
| 2012-03-31 | $47.10B | $8.39B | 17.82% |
| 2011-12-31 | $47.27B | $7.41B | 15.67% |
| 2011-09-30 | $45.65B | $6.56B | 14.36% |
| 2011-06-30 | $44.35B | $5.47B | 12.33% |
| 2011-03-31 | $42.93B | $6.49B | 15.12% |
| 2010-12-31 | $41.26B | $7.44B | 18.02% |
| 2010-09-30 | $41.28B | $9.46B | 22.92% |
| 2010-06-30 | $41.42B | $9.82B | 23.72% |
| 2010-03-31 | $41.35B | $8.98B | 21.72% |
| 2009-12-31 | $40.79B | $8.46B | 20.74% |
| 2009-09-30 | $40.53B | $5.28B | 13.02% |
| 2009-06-30 | $39.73B | $5.46B | 13.74% |
| 2009-03-31 | $39.56B | $5.81B | 14.69% |
| 2008-12-31 | $40.89B | $6.12B | 14.98% |
| 2008-09-30 | $41.42B | $8.43B | 20.34% |
| 2008-06-30 | $41.43B | $8.16B | 19.70% |
| 2008-03-31 | $40.37B | $8.06B | 19.97% |
| 2007-12-31 | $39.59B | $7.91B | 19.98% |
| 2007-09-30 | $38.72B | $7.14B | 18.45% |
| 2007-06-30 | $37.43B | $6.63B | 17.71% |
| 2007-03-31 | $36.97B | $6.01B | 16.26% |
| 2006-12-31 | $35.70B | $5.97B | 16.71% |
| 2006-09-30 | $34.55B | $6.16B | 17.83% |
| 2006-06-30 | $34.49B | $5.20B | 15.07% |
| 2006-03-31 | $34.02B | $4.67B | 13.73% |
| 2005-12-31 | $33.98B | $3.29B | 9.69% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $111.560B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $984.419B | 47.35 |
| Johnson & Johnson (JNJ) | United States | $525.732B | 21.02 |
| AbbVie (ABBV) | United States | $378.291B | 22.65 |
| Roche Holding AG (RHHBY) | Switzerland | $346.748B | 0.00 |
| Novartis AG (NVS) | Switzerland | $303.302B | 16.08 |
| Merck (MRK) | United States | $271.657B | 12.65 |
| Novo Nordisk (NVO) | Denmark | $270.936B | 15.89 |
| Pfizer (PFE) | United States | $145.099B | 7.97 |
| Bayer (BAYRY) | Germany | $49.161B | 8.63 |
| Innoviva (INVA) | United States | $1.462B | 7.32 |